Cardiol Therapeutics (CRDL) Change in Accured Expenses (2022 - 2026)

Cardiol Therapeutics' Change in Accured Expenses history runs 4 years deep, the most recent figure standing at $1.1 million for Q1 2026.

• Quarterly Change in Accured Expenses changed N/A year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $961119.1 (changed N/A YoY) and the FY2021 annual result came in at -$3.9 million, changed N/A from the prior year.
• Change in Accured Expenses was $1.1 million for Q1 2026 at Cardiol Therapeutics, up from -$991150.5 in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $1.3 million in Q1 2024 and bottomed at -$1.7 million in Q1 2022.
• A 4-year average of -$242962.4 and a median of -$399157.2 in 2023 frame the typical range for Change in Accured Expenses.
• Peak annual rise in Change in Accured Expenses reached 2549.36% in 2024, while the deepest fall reached 238.21% in 2024.
• Cardiol Therapeutics' Change in Accured Expenses stood at -$1.3 million in 2022, then jumped by 77.82% to -$293061.9 in 2023, then sank by 238.21% to -$991150.5 in 2024, then jumped by 212.53% to $1.1 million in 2026.
• Business Quant data shows CRDL's Change in Accured Expenses at $1.1 million in Q1 2026, -$991150.5 in Q3 2024, and -$505252.5 in Q2 2024.